Sorafenib enhanced the function of myeloid-derived suppressor cells in hepatocellular carcinoma by facilitating PPARα-mediated fatty acid oxidation

Abstract Background Sorafenib, an FDA-approved drug for advanced hepatocellular carcinoma (HCC), faces resistance issues, partly due to myeloid-derived suppressor cells (MDSCs) that enhance immunosuppression in the tumor microenvironment (TME). Methods Various murine HCC cell lines and MDSCs were us...

Full description

Bibliographic Details
Published in:Molecular Cancer
Main Authors: Chunxiao Li, Liting Xiong, Yuhan Yang, Ping Jiang, Junjie Wang, Mengyuan Li, Shuhua Wei, Suqing Tian, Yuexuan Wang, Mi Zhang, Jie Tang
Format: Article
Language:English
Published: BMC 2025-01-01
Subjects:
Sorafenib
Hepatocellular carcinoma
Myeloid-derived suppressor cells
MDSCs
Macrophages
Online Access:https://doi.org/10.1186/s12943-025-02238-5

Internet

https://doi.org/10.1186/s12943-025-02238-5

Similar Items